Comparison of total, complexed and free prostate-specific antigens and                their ratios in the detection of prostate cancer in a non-screened                population

Pa, McArdle; Pollock, M A.; Wallace, Andrew M.; McMillan, Donald C.; Crooks, JE; Underwood, M.A.

doi:10.1258/000456304323019569

Cited by 4 publications

(3 citation statements)

References 13 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other authors used the 95th sensitivity percentile to defi ne cut-off values and obtained differing results [8,9] . We considered two pairs of cut-off values suitable for clinical application, the 95% sensitivity threshold (in this study 2.0 ng/ml for complexed and 2.5 ng/ml for total PSA) and 3.0 ng/ml for complexed PSA and 4.0 for total PSA in agreement with values suggested by others [3,12] and with the most commonly used total PSA threshold of 4.0 ng/ml. At these cut-offs, there was no appreciable difference in the performance of the complexed and total PSA tests in our study refl ected by the associated specifi city and positive and negative predictive values.…”

Section: Discussionmentioning

confidence: 64%

“…Compared to ROC curves, defi nite cut-off values are likely to be preferred in the clinical setting. Some authors report rather arbitrary cut-off values for complexed and total PSA (for instance 2.9 ng/ml for complexed PSA and 3.9 ng/ml for total PSA representing the 93rd sensitivity percentile [3] or 2.9 for complexed PSA and 4.0 ng/ml for total PSA representing the 90th sensitivity percentile in their studies [12] ) or a broad range of possible cut-off values for complexed PSA [2] . Other authors used the 95th sensitivity percentile to defi ne cut-off values and obtained differing results [8,9] .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of the Clinical Value of Complexed PSA and Total PSA in the Discrimination between Benign Prostatic Hyperplasia and Prostate Cancer

Froehner¹,

Hakenberg²,

Koch

et al. 2006

Urol Int

View full text Add to dashboard Cite

Background: To compare the clinical value of the measurement of complex and total PSA in the discrimination between benign prostatic hyperplasia (BPH) and prostate cancer. Methods: In serum samples collected from 166 men with histopathologically proven clinically localized prostate cancer and of 97 men with BPH, total prostate-specific antigen (PSA), complexed PSA and the free to total PSA ratio were determined. The statistical analysis was done by the comparison of the receiver operator characteristic (ROC) curves. Results: The areas under the ROC curves were 0.776 for total PSA, 0.799 for complexed PSA (total PSA vs. cPSA: p < 0.0001) and 0.812 for the free to total PSA ratio. With a cut-off of 3.0 ng/ml for complexed PSA, the sensitivity was 90%, the specificity 58%, the positive and the negative predictive values 79 and 78%, respectively. With a cut-off of 4.0 ng/ml for total PSA, the sensitivity was 87%, the specificity 59%, the positive and the negative predictive values were 78 and 72%, respectively. Conclusions: There was a statistically significant advantage for complexed PSA compared to total PSA in the discrimination between BPH and prostate cancer. The difference was, however, small and its clinical relevance is questionable.

show abstract

Section: Discussionmentioning

confidence: 64%

Section: Discussionmentioning

confidence: 99%

Comparison of the Clinical Value of Complexed PSA and Total PSA in the Discrimination between Benign Prostatic Hyperplasia and Prostate Cancer

Froehner¹,

Hakenberg²,

Koch

et al. 2006

Urol Int

View full text Add to dashboard Cite

show abstract

“…Generally, multiple molecular isoforms of PSA circulate in serum [ 32 , 34 ]. For instance, approximately 70% of PSA can be found in serum as complexed PSA (cPSA), in which PSA is bound to serine protease inhibitors, such as α1-antichymotrypsin (ACT) and α2-macroglobulin [ 35 , 36 ].…”

Section: Potential Pca Protein Biomarkersmentioning

confidence: 99%

Multiplexed Prostate Cancer Companion Diagnostic Devices

Aidoo-Brown

Moschou

Estrela

2021

Sensors

View full text Add to dashboard Cite

Prostate cancer (PCa) remains one of the most prominent forms of cancer for men. Since the early 1990s, Prostate-Specific Antigen (PSA) has been a commonly recognized PCa-associated protein biomarker. However, PSA testing has been shown to lack in specificity and sensitivity when needed to diagnose, monitor and/or treat PCa patients successfully. One enhancement could include the simultaneous detection of multiple PCa-associated protein biomarkers alongside PSA, also known as multiplexing. If conventional methods such as the enzyme-linked immunosorbent assay (ELISA) are used, multiplexed detection of such protein biomarkers can result in an increase in the required sample volume, in the complexity of the analytical procedures, and in adding to the cost. Using companion diagnostic devices such as biosensors, which can be portable and cost-effective with multiplexing capacities, may address these limitations. This review explores recent research for multiplexed PCa protein biomarker detection using optical and electrochemical biosensor platforms. Some of the novel and potential serum-based PCa protein biomarkers will be discussed in this review. In addition, this review discusses the importance of converting research protocols into multiplex point-of-care testing (xPOCT) devices to be used in near-patient settings, providing a more personalized approach to PCa patients’ diagnostic, surveillance and treatment management.

show abstract

A sensitive immunochromatographic assay using gold nanoparticles for the semiquantitative detection of prostate-specific antigen in serum

Nagatani

Yuhi²,

Chikae

et al. 2006

Nanobiotechnol

View full text Add to dashboard Cite

Comparison of total, complexed and free prostate-specific antigens and their ratios in the detection of prostate cancer in a non-screened population

Abstract: These results show that in patients with total PSA concentrations between 2 and 10 micro g/L, the free-to-total PSA ratio was superior to total PSA concentration in discriminating between patients with benign and malignant disease.

Cited by 4 publications

References 13 publications

Comparison of the Clinical Value of Complexed PSA and Total PSA in the Discrimination between Benign Prostatic Hyperplasia and Prostate Cancer

Comparison of the Clinical Value of Complexed PSA and Total PSA in the Discrimination between Benign Prostatic Hyperplasia and Prostate Cancer

Multiplexed Prostate Cancer Companion Diagnostic Devices

A sensitive immunochromatographic assay using gold nanoparticles for the semiquantitative detection of prostate-specific antigen in serum

Contact Info

Product

Resources

About